Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers August 2, 2015
Pharmacy Choice - News - Generic Drugs - August 2, 2015

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

8/1/15 - BRIEF: Trib 30 index slips in July; 29 percent drop makes ATI biggest loser [The Pittsburgh Tribune-Review]
Generic drugmaker Mylan NV dropped 18 percent since Teva Pharmaceutical Industries dropped an unsolicited bid for the company. Nine companies American Eagle Outfitters, Ansys, Bank of New York Mellon, Comcast, First Commonwealth, FNB Corp., Matthews International, PNC Financial and Thermo Fisher Scientific logged 52- week highs during the month
8/1/15 - United States : US FDA approves Sofgen's Nimodipine 30mg capsule [TendersInfo (India)]
ANI Pharmaceuticals, Inc. disclosed that its ANDA collaboration partner Sofgen has obtained approval from the US Food and Drug Administration for its Abbreviated New Drug Application for Nimodipine 30 mg capsules. According to IMS Health, trailing twelve-month sales for the product are $25 million with two current competitors. Arthur S. Przybyl, pr
8/1/15 - UPDATE2: Pacific Rim nations short of final free trade deal: sources
In Hawaii, the 12 countries remained at odds over patent periods for next-generation medicines, with the United States calling for around 10 years to benefit pharmaceutical companies and Australia proposing five years to encourage generic drug production. New Zealand's demand for greater access to dairy markets in countries such as Canada and Japan
7/31/15 - Astrazeneca's revenue better than forecast
ASTRAZENECA revenue fell by a smaller-than-expected seven per cent in the second quarter, as income from selling rights to medicines offset generic competition to older drugs and a strong dollar. The drugmaker increased its revenue forecast for the year and said it now expected a low single-digit percentage decline, against mid single-digit previou
7/31/15 - Hospira Announces U.S. Launch of Generic Bivalirudin for Injection
By a News Reporter-Staff News Editor at Health& Medicine Week Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, announced it had obtained U.S. Food and Drug Administration approval for the launch of bivalirudin for injection, a generic version of The Medicines Company's
7/31/15 - In vivo study of generic drug products in human subjects [TendersInfo (India)]
Solicitation: In vivo study of generic drug products in human subjects Response Date: Aug 13, 2015 Archiving Policy: Automatic, on specified date Archive Date: August 14, 2015 Major organization: DEPARTMENT OF HEALTH AND HUMAN SERVICES Address: 5630 Fishers Lane Room 2129 Rockville Maryland 20857-0001 Primary Point of Contact: Linda Troutman, Contr
7/31/15 - Investigators from Chugai Pharmaceutical Target Colony-Stimulating Factors (Effective use of modeling and simulation in designing bioequivalence and...
According to news reporting originating from Tokyo, Japan, by NewsRx correspondents, research stated, "Bioequivalence and comparability studies are necessary for changing formulations of large-molecule drugs, such as antibody drugs and protein products, and in the development of their biosimilars. For more information on this research see: Effectiv
7/31/15 - Israel,United States : TEVA PHARMACEUTICAL seeks to take over Allergan`s generics unit [TendersInfo (India)]
Teva Pharmaceutical Industries Ltd is planning to purchase Allergan PLC s generics unit for $40.5 billion. Allergan would be paid with $33.75 billion in cash from Teva and with shares worth around $6.75 billion, which would make up for about 10% of the company s possession. DealBook s Chad Bray says, The Allergan deal cements Teva s position as the
7/31/15 - Jordan : HIKMA PHARMACEUTICALS to acquire generic drug maker for $2.65B [TendersInfo (India)]
The deal will see Hikma paying $1.18 billion in cash and issue 40 million new Hikma shares, or 16.71% of its expanded stock capital, to the German seller. Hikma based the valuation on an agreed stock price of 2,350 pence per Hikma stock, a 13% premium over Monday's London close, and an exchange rate of $1.56 to the British pound. For Hikma, the acq
7/31/15 - Middle Eastern Business Headlines At 6:12 a.m. GMT
Explosion shuts down Iran-Turkey natural gas pipeline UAE slashes fuel subsidies, announces 24 percent price hike Dubai launches expansion of Mideast's biggest port Cyprus, Israel seek to bolster energy, security cooperation Israel's Teva buys Allergan generic drug company for $40.5 B Russia to upgrade air defense missiles intended for Iran Austral
7/31/15 - Middle Eastern Business Headlines At 6:44 a.m. GMT
Explosion shuts down Iran-Turkey natural gas pipeline UAE slashes fuel subsidies, announces 24 percent price hike Dubai launches expansion of Mideast's biggest port Cyprus, Israel seek to bolster energy, security cooperation Israel's Teva buys Allergan generic drug company for $40.5 B Russia to upgrade air defense missiles intended for Iran Austral
7/31/15 - Pharmaceutical products [TendersInfo (India)]
Contract award: purchase with the delivery of drugs overall, preparations for anesthesia and premedication, oncology, drugs affecting bone mineralization, buffered formalin, hemostatic dressings for hospital pharmacies holy cross cancer center in kielce. The contract is for the purchase and the supply of generic drugs, preparations for anesthesia a
7/31/15 - Romark Laboratories and Lupin Pharmaceuticals Respond to Recent Cryptosporidium (Crypto) Outbreak in Dallas [Manufacturing Close - Up]
According to a media release, Romark Laboratories is a Tampa- based pharmaceutical company committed to the discovery, development and commercialization of innovative small molecules for treating infectious diseases, and Lupin Pharmaceuticals is the 6th largest pharmaceutical company in the U.S. with a wide portfolio of generic and branded medicine
7/31/15 - Teva Secures $33.75 Billion Financing Commitment
Teva Pharmaceutical Industries Ltd. today announced that it has entered into commitment letters relating to its pending acquisition of Allergan s generic pharmaceuticals business with Bank of America Merrill Lynch, Barclays Bank PLC, BNP Paribas, Citi, Credit Suisse, HSBC, Mizuho Bank, Morgan Stanley Senior Funding, Inc., RBC Capital Markets and
7/31/15 - United States : HIKMA PHARMACEUTICALS buys U.S. Generic Pharmaceutical Business [TendersInfo (India)]
The organization would buy 100% stock in Roxane Labs Inc., which is the collective name for Boehringer s generic pharmaceutical business, Roxanne Laboratories Inc., and its manufacturing supply chain affiliate, Boehringer Ingelheim Roxane Inc.. The $2.65 billion valuation comes from up-front payments, plus milestones and royalties related to certai
7/30/15 - Allergan Confirms Generic Tyvaso Patent Challenge
WASHINGTON- Allergan Plc. confirmed that it has filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration, seeking approval to market Treprostinil Inhalation Solution, 0.6 mg/mL, 2.9 mL ampules. Allergan's ANDA product is a generic version of United Therapeutics Corporation's Tyvaso, which is indicated for the treatment o
7/30/15 - Allergan Confirms Generic Tyvaso Patent Challenge
Allergan's ANDA product is a generic version of United Therapeutics Corporation's Tyvaso , which is indicated for the treatment of pulmonary arterial hypertension to improve exercise ability. United Therapeutics filed suit against Allergan on July 22, 2015 in the U.S. District Court for the District of New Jersey seeking to prevent Allergan from.
7/30/15 - Anglo-Swedish drug firm AstraZeneca reports slide in second quarter profits
LONDON Anglo-Swedish drug firm AstraZeneca says second-quarter net income fell 12 per cent to $697 million as competition from generic drug companies reduced sales.
7/30/15 - Cardinal Health Lifts 2016 Outlook As Q4 Results Beat View
WASHINGTON- Healthcare provider Cardinal Health, Inc. on Thursday reported a 26 percent increase in profit for the fourth quarter from last year, reflecting higher revenues at both its pharmaceutical and medical segments. Earlier in July, Cardinal Health completed the $1.115 billion acquisition of privately-held generic drug distributor Harvard Dru
7/30/15 - Copaxone sales hit new record [Globes, Tel Aviv, Israel]
July 30 Teva Pharmaceutical Industries Ltd. published its results for the second quarter of 2015 today. Much attention was focused on sales of Teva's flagship Copaxone drug for the treatment of multiple sclerosis, which has faced competition from Sandoz's generic version Glatopa since June 18. Despite the competition, global sales of Copaxone amo
7/30/15 - Daily Mail, London, market report column [Daily Mail, London]
July 30 ACTIVIST investor GO Investment Partners is expected to increase the pressure on the Premier Farnell board to undergo an aggressive restructuring or merge with rival Electrocomponents. GO recently increased its stake in the FTSE 250 company from 3.24 pc to 4.11 pc after first declaring a shareholding in May. Peel Hunt's analyst Henry Carv
7/30/15 - Drug firm AstraZeneca reports slide in earnings
Anglo-Swedish drug firm AstraZeneca says second-quarter net income fell 12 percent to $697 million as competition from generic drug companies reduced sales. CEO Pascal Soriot says the company made "good progress" in the period, with cost reductions supporting investment in science. Soriot also highlighted progress in the company's oncology resea
7/30/15 - EU Approves Mylan's Acquisition Of Perrigo
BRUSSELS- The European Commission Wednesday said it has approved the acquisition of Perrigo of Ireland by Mylan of the Netherlands, under the EU Merger Regulation. Perrigo is specialized in selling over-the-counter drugs, available without prescription in pharmacies. In the limited instances where both Mylan and Perrigo sell pharmaceutical products
7/30/15 - Ireland,Israel : TEVA PHARMACEUTICAL acquires ALLERGAN GENERICS for $40.5 BILLION [TendersInfo (India)]
Teva Pharmaceutical Industries has agreed to buy Allergan's generic drugs unit for $40.5 billion, after unanimously approved by the Boards of Directors of both the companies. Following the completion of the transaction, Allergan will get $33.75 billion in cash and Teva shares valued at $6.75 bn, which represents a 10% stake in the Israel firm.
7/30/15 - Israel : Teva buys ALLERGAN's generic pharmaceuticals business [TendersInfo (India)]
Enhancing its position as the largest generic drugmaker in the world, Israeli Teva Pharmaceutical Indus tries is buying Allergan's generic pharmaceuticals business in a $40.5 billion deal. The deal will provide Allergan with $33.75 billion in cash and stock of Teva, worth $6.75 billion on Monday. CEO and president of Allergan, Brent Saunders, sai
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2015 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Pharmacy Spanish
This lesson is supported by:
Hands on Spanish
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415